NEWS RELEASE
Brammer Bio Announces Major Milestone in Establishing Commercial-ready Gene Therapy Supply for the Industry
Cambridge, MA, USA, May 09, 2017 - Brammer Bio (“Brammer”), a cell and gene therapy contract development and manufacturing organization (CDMO), today announced that it is on-track to complete the establishment of commercial-ready gene therapy manufacturing capacity in Cambridge, Massachusetts, in the second half of 2017. This follows the January 1, 2017 acquisition of Biogen’s biologics manufacturing facility in Cambridge and distribution center in Somerville, Massachusetts, that included the on-boarding of an experienced team of 100 employees. Further, Brammer completed an FDA Type-C meeting to review the design plans for the Cambridge facility and will submit a Site Master File later this year to support its clients’ product applications.
Brammer now offers a complete range of process development, clinical phase, and Current Good Manufacturing Practices (CGMP) services for cell and gene therapies using multiple platform technologies. Brammer’s extraordinary team of over 250 employees is focused exclusively on serving the cell and gene therapy needs of its clients and their patients.
“We are delighted to add an experienced commercial biologics team and facilities to help meet the needs of this transformative industry,” said Mark Bamforth, president and chief executive officer at Brammer. “We are building on more than a decade of supplying first-in-human cell and gene therapy clinical trials under the leadership of Dr. Richard Snyder, Brammer’s chief scientific officer. Our commercial-ready Cambridge facility will be fully operational by Q4 2017. We appreciate Biogen’s support during the transition of the facilities and skilled manufacturing personnel.”
Originally built for the manufacture of Biogen’s clinical and commercial biologics, the 66,000 square-foot Cambridge facility in the heart of Kendall Square was licensed by regulatory authorities to manufacture four commercial products. Brammer is renovating the facility for late-stage clinical development and commercial launch of gene therapy products. Brammer also acquired Biogen’s nearby 49,000 square-foot, state-of-the-art distribution and warehousing facility, providing high-quality storage and distribution capabilities.
Secretary of Housing and Economic Development for the Commonwealth of Massachusetts, Jay Ash, commented, “By bringing novel medical treatments to patients and retaining biotech manufacturing jobs in Massachusetts, Brammer Bio is enhancing the Commonwealth’s leading position in both life sciences and advanced manufacturing.”
Since completing a merger with Florida Biologix, an Ampersand Capital Partners’ portfolio company, in March 2016, Brammer has doubled its capacity for process development and is expanding its clinical production space in Alachua, Florida. The addition of Massachusetts facilities gives Brammer 230,000 square feet of development, distribution, and CGMP manufacturing facilities. Brammer also previously announced plans to build-out its 50,000 square-foot facility in Lexington, Massachusetts, which is currently being designed for late stage and commercial cell therapy supply.
For media inquiries contact:
Lynn Costa
lynn.costa@brammerbio.com
Media: +1 781 924 6551
Brammer Bio addresses:
13859 Progress Boulevard
Alachua, FL 32615
250 Binney Street
Cambridge, MA 02142
Brammer Bio website and contact info:
www.brammerbio.com
Sales inquiries: +1 877 765 7676
E-mail: info@brammerbio.com
Brammer now offers a complete range of process development, clinical phase, and Current Good Manufacturing Practices (CGMP) services for cell and gene therapies using multiple platform technologies. Brammer’s extraordinary team of over 250 employees is focused exclusively on serving the cell and gene therapy needs of its clients and their patients.
“We are delighted to add an experienced commercial biologics team and facilities to help meet the needs of this transformative industry,” said Mark Bamforth, president and chief executive officer at Brammer. “We are building on more than a decade of supplying first-in-human cell and gene therapy clinical trials under the leadership of Dr. Richard Snyder, Brammer’s chief scientific officer. Our commercial-ready Cambridge facility will be fully operational by Q4 2017. We appreciate Biogen’s support during the transition of the facilities and skilled manufacturing personnel.”
Originally built for the manufacture of Biogen’s clinical and commercial biologics, the 66,000 square-foot Cambridge facility in the heart of Kendall Square was licensed by regulatory authorities to manufacture four commercial products. Brammer is renovating the facility for late-stage clinical development and commercial launch of gene therapy products. Brammer also acquired Biogen’s nearby 49,000 square-foot, state-of-the-art distribution and warehousing facility, providing high-quality storage and distribution capabilities.
Secretary of Housing and Economic Development for the Commonwealth of Massachusetts, Jay Ash, commented, “By bringing novel medical treatments to patients and retaining biotech manufacturing jobs in Massachusetts, Brammer Bio is enhancing the Commonwealth’s leading position in both life sciences and advanced manufacturing.”
Since completing a merger with Florida Biologix, an Ampersand Capital Partners’ portfolio company, in March 2016, Brammer has doubled its capacity for process development and is expanding its clinical production space in Alachua, Florida. The addition of Massachusetts facilities gives Brammer 230,000 square feet of development, distribution, and CGMP manufacturing facilities. Brammer also previously announced plans to build-out its 50,000 square-foot facility in Lexington, Massachusetts, which is currently being designed for late stage and commercial cell therapy supply.
About Brammer Bio
Brammer Bio offers clinical and commercial services to supply vectors for in vivo gene therapy and ex vivo modified-cell based therapy. This includes process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients’ health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders. For more information, please visit www.brammerbio.com.About Ampersand Capital Partners
Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Visit www.ampersandcapital.com.For media inquiries contact:
Lynn Costa
lynn.costa@brammerbio.com
Media: +1 781 924 6551
Brammer Bio addresses:
13859 Progress Boulevard
Alachua, FL 32615
250 Binney Street
Cambridge, MA 02142
Brammer Bio website and contact info:
www.brammerbio.com
Sales inquiries: +1 877 765 7676
E-mail: info@brammerbio.com